PDCD1 and esophageal squamous cell carcinoma: Recently, a randomized phase III trial (ASTRUM-007) in China investigated chemotherapy with the programmed cell death protein-1 (PD-1) inhibitor serplulimab for PD-L1-positive advanced ESCC patients.